SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-039521
Filing Date
2023-11-06
Accepted
2023-11-06 16:06:00
Documents
69
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1227232
2 ex31-1.htm EX-31.1 12862
3 ex32-1.htm EX-32.1 6793
  Complete submission text file 0001493152-23-039521.txt   6898602

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ards-20230930.xsd EX-101.SCH 61090
5 XBRL CALCULATION FILE ards-20230930_cal.xml EX-101.CAL 61468
6 XBRL DEFINITION FILE ards-20230930_def.xml EX-101.DEF 271502
7 XBRL LABEL FILE ards-20230930_lab.xml EX-101.LAB 455498
8 XBRL PRESENTATION FILE ards-20230930_pre.xml EX-101.PRE 367670
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1058749
Mailing Address 983 UNIVERSITY AVENUE, BLDG. B LOS GATOS CA 95032
Business Address 983 UNIVERSITY AVENUE, BLDG. B LOS GATOS CA 95032 (408) 385-1742
Aridis Pharmaceuticals, Inc. (Filer) CIK: 0001614067 (see all company filings)

IRS No.: 320074500 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38630 | Film No.: 231379981
SIC: 2834 Pharmaceutical Preparations